Oculis Holding AG (OCS) Cash from Investing Activities (2022 - 2024)
Oculis Holding AG's (OCS) quarterly Cash from Investing Activities came in at -$19.7 million in Q2 2024, down 738.58% quarter-over-quarter from -$2.3 million in Q1 2024.
Oculis Holding AG (OCS) Cash from Investing Activities (2022 - 2024) Analysis & Trends
Oculis Holding AG's Cash from Investing Activities history runs 3 years deep, the most recent figure standing at -$19.7 million for Q2 2024.
- On a quarterly basis, Cash from Investing Activities changed N/A year-over-year to -$19.7 million in Q2 2024; TTM through Jun 2024 was -$464875.5, a N/A change from a year earlier, with the FY2025 full-year figure at -$73.5 million, down 302.01% from the prior year.
- Cash from Investing Activities declined to -$19.7 million in Q2 2024 per OCS's latest filing, from -$2.3 million in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $25.9 million in Q4 2023 and bottomed at -$19.7 million in Q2 2024.
- The 3-year median for Cash from Investing Activities is -$2.0 million (2024), against an average of -$427938.7.
- Biggest YoY gain for Cash from Investing Activities was 1744.57% in 2023; the steepest drop was 714.06% in 2023.
- Year by year, Cash from Investing Activities stood at -$1.6 million in 2022, then jumped by 1744.57% to $25.9 million in 2023, then sank by 176.04% to -$19.7 million in 2024.
- Per Business Quant, the three latest OCS Cash from Investing Activities figures stand at -$19.7 million (Q2 2024), -$2.3 million (Q1 2024), and $25.9 million (Q4 2023).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | -45.51 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | -431.90 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | -428.90 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 172.62 Mn |
| 10 | Alnylam Pharmaceuticals | 36.08 Bn | 33.07 Bn | 959.66 Mn | -25.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | -19.67 Mn |
| Jun 30, 2024 | -19.67 Mn |
| Mar 31, 2024 | -2.35 Mn |
| Mar 31, 2024 | -2.35 Mn |
| Dec 31, 2023 | 25.86 Mn |
| Dec 31, 2023 | 25.86 Mn |
| Sep 30, 2023 | -4.32 Mn |
| Sep 30, 2023 | -4.32 Mn |
| Dec 31, 2022 | -1.57 Mn |
| Dec 31, 2022 | -1.57 Mn |
| Sep 30, 2022 | -530,153.80 |
| Sep 30, 2022 | -530,153.80 |